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Background: To investigate associations between WW domain-containing oxidoreductase (WWOX), runt-related
transcription factor 2 (RUNX2) and vascular endothelial growth factor alpha (VEGFA) in human osteosarcoma (OS).
Methods: Copy number aberrations of WWOX, RUNX2and VEGFA genes were detected by microarray comparative
genomic hybridization (aCGH) in 10 fresh OS tissue samples. VEGFA gene alterations were also investigated and
validated by fluorescence in situ hybridization (FISH) in 54 formalin-fixed and paraffin-embedded (FFPE) OS samples.
Protein expression of WWOX, RUNX2 and VEGFA were examined in 54 FFPE OS samples by immunohistochemistry
(IHC).
Results: Analysis of previously published OS aCGH data (GSE9654) and aCGH data from this study (GSE19180)
identified significant deletion of WWOX in 30% (6/20) of OS samples, whilst significant increase in both RUNX2 and
VEGFA gene copy numbers were detected in 55% (11/20) and 60% (12/20) of OS samples, respectively. FISH
demonstrated increased VEGFA gene copy number in 65.9% (31/47) of evaluable samples, in either focal or large
fragment forms. Compared with positive expression of WWOX in 38.9% of the OS samples, positive expression of
RUNX2 and VEGFA protein was found in 48.1 and 75.9% of samples. Although there was no significant association
between gene copy number aberration and protein expression for WWOX and RUNX2, significant positive
correlation between increased VEGFA gene copy number and VEGFA protein expression was observed. Although
there was no significant reverse association between WWOX and RUNX2 expression, a significantly positive
relationship was observed between RUNX2 and VEGFA protein expression.
Conclusions: Our data show increased RUNX2 and VEGFA gene copy numbers and elevation of their respective
proteins in human OS. Positive correlation of RUNX2 and VEGFA suggests that both increased VEGFA gene copy
number and RUNX2 overexpression facilitate increased expression of VEGFA.
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Osteosarcoma (OS) is the most common, primary, ma-
lignant bone tumor within the non-hematopoietic sys-
tem. OS frequently occurs in the metaphysis of actively
growing long bones and is characteristic of short and
rapid progression. It has high incidence of pulmonary
metastasis and poor prognosis, and mainly affects children
and adolescents [1]. Because of a complexity of karyotypes
and a highly unstable genome, OS usually exhibits both
numerical and structural chromosomal alterations [2]. As* Correspondence: yangjilong@tjmuch.com
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reproduction in any medium, provided the ora putative tumor suppressor gene, WWOX is located at
chromosome 16q23.3-q24.1, spanning common fragile site
FRA16D [3]. WWOX is detected as functional loss or fre-
quent attenuation of protein expression in combination
with poor prognosis. This often results from abnormal
mRNA splicing of WWOX, missing exons, loss of het-
erozygosity (LOH) and hypermethylation in numerous
carcinomas [4-9].WWOX might play tumor-suppressor
function through interaction with TNF, p53, Bcl-2,
ErbB-4 and c-Jun [3,10-12]. A recent study indicated
that WWOX was physically and functionally associated
with RUNX2 and can suppress RUNX2 transactivation
by interaction between the first WW domain and
RUNX2 [13]. In addition, absence of WWOX seems tod. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Yang et al. BMC Medical Genomics 2013, 6:56 Page 2 of 8
http://www.biomedcentral.com/1755-8794/6/56contribute to increased RUNX2 expression, further
affecting bone growth and metabolism, initiating OS
tumorigenesis [14].
The RUNX2 region (6p12-21) is often detected in OS
using gene amplification and protein overexpression,
suggesting upregulation of this gene and its protein is
associated with tumorigenesis, progression, metastasis
and unfavorable outcome [15-21]. Importantly, Kyle and
colleagues observed an inverse relationship between
WWOX and RUNX2 expression in WWOX-deficient
mice and OS cell lines [14]. Additionally, RUNX2 is
a critical element for VEGF mRNA transcription and
protein expression in tumorigenesis [22]. Aqeilan and
colleagues found that ectopic expression of WWOX
in MDAMB231 breast cancer reduced expression of
RUNX2 and its target genes, including VEGF [13]. How-
ever, little is known about the correlation of WWOX,
RUNX2 and VEGF in human OS tissues. In this study,
we observed WWOX, RUNX2 and VEGFA gene copy
number status and protein expression levels using
microarray comparative genomic hybridization (aCGH),Table 1 RUNX2 and VEGFA protein expression level and their
Characteristics RUNX2
- + ++ +
Sex
Male (26) 15 4 1
Female (28) 13 9 2
Age groups
≤15 y (14) 8 3 0
15–20 y (22) 11 7 2
21–30 y (9) 5 2 0
31–40 y (1) 0 0 1
>40 y (8) 4 1 0
PTNM stage
I stage (4) 2 1 0
II stage (18) 8 4 3
III stage (2) 2 0 0
IV stage (1) 1 0 0
Recurrence
No (47) 26 11 2
Yes (7) 2 2 1
Metastasis
No (35) 19 8 2
Yes (11) 5 3 1
Disease free survival (mean months ± sd) Log Rankχ2 = 1.331
(60.238 ± 7.881)
Overall survival (mean months ± sd) Log Rankχ2 = 0.984
*Significantly different P < 0.05.immunohistochemistry (IHC) staining and fluorescence
in situ hybridization (FISH), in order to investigate cor-
relations between these components.
Methods
Clinical information for OS tissues
Ten fresh OS tissue biopsies were obtained for aCGH
analysis. Fifty-four formalin-fixed and paraffin-embedded
(FFPE) OS tissues were obtained for FISH and IHC ana-
lysis (including nine aCGH analysis samples. One case
which had aCGH data was excluded from further assay
because of no enough sample). Clinicopathological charac-
teristics comprised age, sex, pTNM stage, recurrence and
metastasis (Table 1). Disease-free and overall survival rate
ranged from 0 to 94 months, with medians of 7.5 and
12 months, respectively. All samples and clinical data were
obtained and analyzed at Tianjin Medical University
Cancer Institute and Hospital, China. The study and all
procedures were approved by the Institutional Review
Board (IRB) at Tianjin Medical University Cancer Institute
& Hospital (TMUCIH).correlation with clinical pathologic factors
VEGFA
++ P value - + ++ +++ P value
6 0.435 10 5 4 7 0.012*
4 3 17 2 6
3 0.027* 4 6 0 4 0.730
2 5 9 2 6
2 1 4 2 2
0 1 0 0 0
3 2 3 2 1
1 0.906 0 3 1 0 0.168
3 5 5 1 7
0 0 1 1 0
0 1 0 0 0
8 0.484 13 20 4 10 0.132
2 0 2 2 3
6 0.951 11 14 3 7 0.351
2 1 4 2 4
0.722 Log Rankχ2 = 6.277
(60.238 ± 7.881)
0.099
0.805 Log Rankχ2 = 0.471
(70.903 ± 6.737)
0.925
Yang et al. BMC Medical Genomics 2013, 6:56 Page 3 of 8
http://www.biomedcentral.com/1755-8794/6/56aCGH investigation and data analysis
aCGH was performed as previously described [23].
Labeled genomic DNAs were hybridized using the Agilent
Human Genome CGH Microarray (4 × 44 k) (Agilent
Technologies, Palo Alto, CA).Genomic DNA was isolated
according to standard procedure. These arrays represent
over 43,000 coding and non-coding human sequences,
yielding an average 35kbp oligonucleotide probe spatial
resolution. At least one target sequence was measured for
every characterized gene, and known cancer genes were
measured using a minimum of two probes. Probes were
designed based on the University of California Santa Cruz
hg17 human genome (National Center for Biotechnology
build 35, May 2004). aCGH analysis was also carried out
as previously described [23]. Briefly, ratio of intensity
values from tumor and normal tissues was transformed
to log2-space. Log ratio data were then subjected to a
circular binary segmentation (CBS) algorithm to reduce
the effect of noise. Following this, a CGHcall algorithm
was used to give each segment an aberration label: normal,
deletion, or amplification. All our aCGH data can be
accessed through the GEO ID GSE19180. Previously
published aCGH data (GSE9654) was downloaded to
perform the analysis [20].
FISH detection and data analysis
FISH detection and analysis was performed in 54 FFPE
OS samples as previously described [24]. FISH was
performed using the VEGFA probe(Empire Genomics,
Buffalo, NY) for detection and the CEP 6 probe(Abbott
Molecular, Abbott Park, IL) as the reference. The VEGFA
probe was hybridized to the short arm of chromosome 6
(6p12), producing an orange signal, the intensity of which
represented the VEGFA gene copy number. The CEP 6
probe was hybridized to the chromosome 6 centromere
(6p11.1-q11.1), producing a green signal.
FISH results were interpreted independently and
blinded by two pathologists [25]. Copy number alter-
ations in which >90% of nuclei showed hybridization
signals were considered informative. An informative
case was considered VEGFA amplification if the ratio of
orange to green signals was greater than 1 and there
were more than two orange and green signals in each
single tumor cell. If the ratio was equal to 1 and there
were more than two green and orange signals in each
single tumor cell, the case was considered to have
increased VEGFA gene copy number. A case with a ratio
lower than 1 or with only two green and orange signals
in each single tumor cell was considered to have no
VEGFA amplification [24].
IHC analysis
Fifty-four representative FFPE sections were obtained for
IHC staining as previously described [14,23,24]. Antibodiesfor WWOX, RUNX2 and VEGFA were purchased from
Abcam (Abcam company, Cambridge, UK) with dilutions
of 1:500, 1:100 and 1:100, respectively. Skin tissue, fetal
cartilage from abortion tissue and breast carcinoma tissue
served as positive controls for WWOX, RUNX2 and
VEGFA staining, respectively. For negative controls,
primary antibodies were substituted by PBS.
Two pathologists, blinded to the clinical information,
evaluated and scored the IHC staining. Scoring of cyto-
plasmic WWOX and VEGFA staining, and of nuclear
RUNX2 staining, was based on the staining intensity and
extent. Microscopically, each section was observed ran-
domly within 10 high-power fields(40×), each of which
included 100 cells. First, staining extent was evaluated
according to the proportion of positive tumor cells: 0%
(score 0), <10% (score 1), 11‒25% (score 2), 26‒50%
(score 3), 51‒75% (score 4) and > 75% (score 5). Then
staining intensity was scored: no cell stain (score 0), yellow
(score 1), tan (score 2) and brown (score 3). Final scores
were calculated by multiplying intensity and extent
scores and the results were divided as follows: negative
("-", score 0‒1), weak positive (" + ", score 2‒4), moder-
ate positive ("++", score 5‒9) and strong positive ("+++",
score 10‒15). For further study, staining results were
also grouped into negative and positive (including weak
positive, moderate positive and strong positive).
Statistical analysis
We adopted SPSS version 16.0 for Windows to analyze
the data. Student´s t-test or ANOVA was used to compare
means, and frequencies were compared by means of the
Chi-Square test. Survival analysis was carried out to in-
spect relevance between survival rate and expression using
the Kaplan–Meier method and log-rank test. Correlations
between the WWOX, RUNX2 and VEGFA genes and
protein expression were assessed using Spearman’s test.
Two-tailed P values less than 0.05 were considered to
be statistically significant.
Results
Deletion of WWOX and frequent amplification of RUNX2
and VEGFA genes in human OS
Analysis of gene copy number alteration in 10 OS sam-
ples (GSE 19180) detected several chromosome genetic
aberrations, including amplification of 1p35,1q23.1–1q21.1,
6p22.1–6p21.31, and 19p13.11–p13.2 and deletion of
5q12.3–5q13.2, 5q14.3–5q22.2, and 13q13.2–13p14.3 [23].
These findings were validated by analyzing genetic aberra-
tions in previously published aCGH data (GSE9654, 10
human OS samples) [20]. The overall recurrent gene copy
alteration patterns of these two independent populations
in two different countries (China and Canada) were very
similar, suggesting that OS from diverse populations
shares common genetic alterations at the gene copy level
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20 OS) to perform further analysis (Figure 1A). Notably,
the 12q13-15 amplification reported in low-grade OS was
not significant in either dataset, nor were the MDM2 and
CDK4 genes located in this region [26,27].
Analysis of the two aCGH data sets, GSE19180 and
GSE 9654, identified a 30% (6/20) deletion rate of the
WWOX gene in 20 human OS patients (3 cases from
GSE19180 and 3 cases from GSE 9654) [23]. Furthermore,
significant amplification of the RUNX2 gene copy number
was observed in 11 OS patients with an amplification
frequency of 55% (11/20; 3 cases from GSE19180 and 8
cases from GSE 9654) (Figure 1B). For the VEGFA gene,
we identified a 60% (12/20) amplification frequency (6
cases from GSE19180 and 6 cases from GSE 9654) in
20 OS patients [24].
To validate the aCGH analysis, FISH was used to detect
VEGFA gene status in 54 human FFPE OS tissues. We de-
tected increased VEGFA gene copy number in 31 of 47Figure 1 Chromosomal and gene aberrations in 20 human osteosarco
aberrations (CNAs). A. The recurrence pattern of CNAs in 20 human OS s
hybridization (aCGH) datasets (GSE19180and GSE9654). The x-axis indicates
frequency of gains (positive)and losses (negative) for each measured aCGH
Dashed lines indicate the thresholds for significant recurrent aberrations. M
thresholds are color-coded to emphasize the locations of significantly recu
green, significantly recurrent deletion; grey, non-significant recurrence of ab
of the 20 OS samples in aCGH datasets GSE9654 and GSE19180 are indicat
S6272–6285 represent the case IDs in GSE19180. Scatters denote copy num
the regional copy number value estimated by the circular binary segmenta
deletion, whereas grey lines denote non-significant amplification or deletioevaluable samples (65.9%) in either focal or large fragment
forms (FISH results were not available for seven samples
because there was insufficient tissue or loss of tissue dur-
ing the pretreatment process) (Figure 2) [24]. From six
samples showing increased VEGFA gene copy numbers
based on the aCGH method (GSE 19180), FISH detected
five samples showing increased VEGFA gene copy num-
ber. These two methods showed a good level of concord-
ance (P = 0.048, r = 0.816).
To analyze possible interaction betweenWWOX, RUNX2
and VEGFA gene copy number aberrations, we applied
Spearman’s correlation test. However, there was no signifi-
cant correlation between any two genes.
Loss of WWOX protein expression, elevated RUNX2 and
VEGFA protein expression in osteosarcoma tissues and
their correlation
WWOX and VEGFA protein expression was predomin-
antly located in the cytoplasmic compartment with RUNX2ma samples and the status of RUNX2 gene copy number
amples are illustrated in 2 microarray-based comparative genomic
chromosome numbers and the y-axis indicates the aberration
probe, arranged based on their genomic coordinates along the x-axis.
easured sequences with aberration frequency that exceeded the
rrent aberrations (red indicates significantly recurrent amplification;
errations). B. RUNX2 gene copy number aberrations in OS. Sample IDs
ed on the bottom. OS1–19 represent the case IDs in GSE9654 and
ber change of the RUNX2 gene. Lines in black and grey color denote
tion (CBS) algorithm. Black lines denote significant amplification or
n. Twelve samples show amplification of the RUNX2 gene.
Figure 2 Detection and validation of increased VEGFA gene copy number by FISH in OS. Using FISH detection, orange represents VEGFA
probe signal (red arrows) and therefore VEGFA copy number, whilst green represents CEP 6 reference probe signal located in the centromere of
chromosome 6 (green arrows). When VEGFA/CEP 6 signal ratios were equal to or higher than 1, and when more than two gene copies of VEGFA
were found per cell in more than 90% of OC cells, increased VEGFA gene copy number was recorded. Two patterns of increased VEGFA copy
number exist in OS, focally or in larger fragment forms (polysomy). A: No copy number aberration of VEGFA gene, B: focally increase VEGFA gene
copy number, C: increased copy number of VEGFA gene in larger fragment form (polysomy).
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loss of WWOX protein expression (Figure 3A) was re-
corded in 61.1% (33/54) of samples with a positive WWOX
expression rate in 38.9% (21/54) of samples (Figure 3B)
[23]. RUNX2 protein expression was detected in 48.1%
(26/54) of samples, including RUNX2 (+): 24.1% (13/54),
(++): 5.6% (3/54) and (+++): 18.5% (10/54) (Figure 3C).
VEGFA protein expression was detected in 75.9% (41/54)
of samples, including VEGFA(+): 40.7% (22/54), (++):
11.1% (6/54) and (+++): 24.1% (13/54) (Figure3D).
Although no statistically significant association was
found between WWOX expression and clinical pathologic
factors, including sex, age, pTNM stage, recurrence, me-
tastasis and survival, we found increased RUNX2 andFigure 3 Protein expression of WWOX, RUNX2 and VEGFA in human
WWOX protein; B: strong positive expression of WWOX protein; C: strong p
VEGFA protein.VEGFA expression was significantly associated with age
(P = 0.027) and sex(P = 0.012), respectively (Table 1).
Compared with increased VEGFA gene copy number,
detected using FISH analysis, we identified a significant
positive association between increased VEGFA gene copy
number (65.9%, 31/47) and increased VEGFA protein ex-
pression (75.9%, 41/54) (P = 0.022) (Table 2). However, no
significant correlation was detected between gene copy
number (GSE 19180, 10 OS samples) and protein expres-
sion for WWOX (n = 10) and RUNX2 (n = 8) (IHC assay
of RUNX2 protein expression was performed in 9 cases
in which fresh samples were used in the aCGH analysis.
One case which had aCGH data was excluded from IHC
assay because of the sample was insufficient. For WWOXOS tissues by IHC (magnification, 40×). A: negative expression of
ositive expression of RUNX2 protein; D: strong positive expression of
Table 2 Correlation between gene copy number aberration and protein expression of WWOX, RUNX2 and VEGFA
Protein expression*
WWOX deletion (detected by
aCGH in 10 samples, GSE 19180) P value
RUNX2 amplification (detected by
aCGH in 10 samples, GSE 19180) P value
No (%) Yes (%) No(%) Yes(%)
Negative 2 (40.0) 3 (100) 0.237 3 (50.0) 3 (100) 0.325
Weak positive 1 (20.0) 0 (0) 0 (0) 0 (0)
Moderate positive 0 (0) 0 (0) 2 (33.3) 0 (0)
Strong positive 2 (40.0) 0 (0) 1 (16.7) 0 (0)
VEGFA protein expression
(detected by IHC in 54 cases)
Increased VEGFA gene copy number
(detected by FISH in 54 cases)** χ2 P value
No (%) Yes (%)
Negative 7 (43.8) 2 (6.5) 9.639 0.022***
Weak positive 5 (31.2) 15 (48.4)
Moderate positive 1 (6.2) 5 (16.1)
Strong positive 3 (18.8) 9 (29.0)
*IHC assay of RUNX2 protein expression was performed in nine cases from which fresh samples were used in the aCGH analysis. One aCGH data case was
excluded from RUNX2 IHC analysis because of insufficient sample. For WWOX protein expression, only eight cases were used in the IHC assay.
**FISH results were unavailable for seven samples because the samples were insufficient and because of loss of tissues during the pretreatment process.
* **Significantly different P < 0.05.
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assay. Therefore, we analyzed copy number alteration of
the WWOX gene and its protein expression in 8 cases
only) (Table 2). Negative RUNX2 protein expression was
observed in all 3 OS samples with RUNX2 amplification
identified using aCGH detection (GSE 19180) (Table 2).
Interestingly, the FFPE samples used for the IHC assay in
these 3 cases were obtained from post-chemotherapy
tissues, therefore this likely reflects the influence of
chemotherapy on RUNX2 expression [14].
In 39.4% (13/33) of OS samples with negative WWOX
expression, RUNX2 was overexpressed, whereas 60.6% of
samples with WWOX expression loss remained RUNX2
negative. However, statistical analysis failed to identify
any significant inverse association between WWOX and
RUNX2 protein expression (P = 0.073, r = 0.246) (Table 3).
IHC analysis revealed 40.7% (22/54) concurrent positive
expression between RUNX2 and VEGFA in OS samples
(Table 3). Furthermore, Spearman’s correlation coefficientTable 3 Correlation between RUNX2 expression and
WWOX/VEGFA expression in OS, detected by IHC in
54 cases
RUNX2 N WWOX VEGFA
- + ++ +++ - + ++ +++
- 28 20 5 1 2 9 13 2 4
+ 13 7 2 3 1 2 8 0 3
++ 3 2 0 0 1 1 0 0 2
+++ 10 4 3 2 1 1 1 4 4
Total 54
Spearman’s correlation coefficient: r = 0.246, P = 0.073(RUNX2 and WWOX);
r = 0.359, P = 0.008(RUNX2 and VEGFA).test showed a significant concordant relationship between
RUNX2 and VEGFA (P = 0.008, r = 0.359) (Table 3).
Discussion
OS is a malignant tumor of bone tissue with unknown
etiology, and the survival rate has failed to improve since
the introduction of chemotherapy [28]. In this study, we
present genetic and molecular alterations and key associ-
ations between WWOX, RUNX2 and VEGFA expression
in human OS. Our data show increased RUNX2 and
VEGFA gene copy number and protein elevation in
human OS. Although significant reverse correlation was
not observed between WWOX and RUNX2, we identified
positive correlation of RUNX2 and VEGFA, suggesting
both increased VEGFA gene copy number and RUNX2
overexpression facilitate increased expression of VEGFA, a
key factor in tumor angiogenesis.
In the present study, we found no significant positive
correlation between WWOX gene deletion (by aCGH)
and reduced WWOX protein expression (by IHC) in
OS. The result could stem from the low sample number
in present study. Furthermore, there are several other
factors involved the aberrant WWOX protein expres-
sion. According to previous reports, loss or attenuation
of WWOX protein expression frequently results following
abnormal mRNA splicing, missing exons, LOH and hyper-
methylation in theWWOX gene [4-9]. Furthermore, treat-
ment such as chemotherapy might affect WWOX protein
expression [14,29]. Aqeilan and colleagues showed that
WWOX levels frequently increase in tumors resected
following chemotherapy when compared with their pri-
mary biopsies. For these tumors, chemotherapy appears
to induce tumor cell normalization rather than death,
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[14,29]. The present study shows that OS samples with
WWOX gene deletion loose protein expression, suggesting
that WWOX gene copy number alteration also remains
an important mechanism in the aberration of WWOX
protein expression.
Consistent with previous reports, our data found RUNX2
gene amplification and overexpression of its protein to be
common in OS [21]. However, we found negative RUNX2
protein expression in three samples with positive RUNX2
gene amplification. Closer assessment of these samples re-
vealed they were obtained from post-chemotherapy tissues,
suggesting chemotherapy may affect RUNX2 expression.
Further evidence for this was found by Aqeilan and col-
leagues [14]. In their study, IHC analysis of 56 OS cases re-
vealed 60% (12/20) pre-treatment biopsies were positive
for RUNX2. However, only 16% (4/25) post-treatment
resections were positive for RUNX2. Paired pre-treatment
biopsy and post-treatment resections were available for 12
OS patients. Eight biopsies were RUNX2 positive and in
all 8 cases (100%) these were RUNX2 negative post-
treatment [14]. We therefore hypothesize that negative ex-
pression of RUNX2 protein in samples with RUNX2 gene
amplification might due to post-treatment. Pre-treatment
tissues would be required to perform such analysis and
support this hypothesis in future studies.
WWOX is known to suppress transactivation of RUNX2
by association with the first WW-domain, therefore
expression of RUNX2 can be promoted in the absence
of WWOX protein [13]. Kyle and colleagues report an
inverse correlation between WWOX and RUNX2 ex-
pression in WWOX-deficient mice and OS cell lines
[14]. In the present study, no significant correlation was
observed between WWOX and RUNX2 expression. In
fact, the inverse relationship between these factors ob-
served by Kyle and colleagues was not evident when
performing paired comparisons, similarly to our study
results [14]. Thus, the relationship between WWOX
and RUNX2 expression in OS remains unclear and
warrants further investigation.
RUNX2 was previously reported as an essential compo-
nent for the stimulation of VEGFA transcription during
bone organogenesis [22]. In the present study, IHC ana-
lysis revealed a significant positive relationship between
RUNX2 and VEGFA protein expression. These data
suggestRUNX2 overexpression can induce increased
VEGFA expression. VEGFA is known as a target of
RUNX2 [22]. These two molecules are synergistic in the
process of angiogenesis, which is in accordance with a
previous report [22]. At the same time, the significant
relation between increased VEGFA gene copy number
and increased VEGFA expression suggests that increased
VEGFA gene copy number is also important in VEGFA
protein expression. These data provide powerful evidencethat increased VEGFA gene copy number and RUNX2
overexpression facilitate increased expression of VEGFA, a
key factor in tumor angiogenesis.
Conclusions
The present study found no significant correlation be-
tween WWOX, RUNX2, and VEGFA genes with respect
to gene copy number aberration. Significant association
was observed between increased VEGFA gene copy num-
ber and protein expression, whilst WWOX and RUNX2
genes failed to show such association. This may be due to
the regulation of other factors in addition to the effect of
pre-treatment. No significant association was observed
between WWOX and RUNX2 protein expression, but a
significantly positive relationship was observed between
RUNX2 and VEGFA protein expression. WWOX, RUNX2
and VEGFA functional crosstalk may be essential for the
pathogenesis and angiogenesis of OS, and this pathway
might provide a new molecular basis for targeted RUNX2-
VEGFA therapy in OS patients.
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